News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
Firm News March 3, 2026
Gibson Dunn Advises Gyre Therapeutics on Its Acquisition of Cullgen
Gibson Dunn is advising Gyre Therapeutics, Inc., an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases, on its acquisition of Cullgen Inc. The all-stock transaction is valued at approximately $300 million.
Firm News February 2, 2026
Gibson Dunn Advises Coterra Energy on $58 Billion Merger with Devon Energy
Gibson Dunn is advising Coterra Energy on its all-stock merger agreement with Devon Energy. The combined company’s enterprise value will …
Firm News September 15, 2025
Gibson Dunn Advises Ardian on Its Sale of Hill Top Energy Center
Gibson Dunn is advising Ardian on its sale of the Hill Top Energy Center, a state-of-the-art combined cycle gas turbine facility in Western Pennsylvania, to Blackstone.
Firm News July 23, 2025
Gibson Dunn Represented XOMA Royalty in the Acquisition of ESSA Pharma by XenoTherapeutics
Gibson Dunn represented XOMA Royalty Corporation in connection with the acquisition of ESSA Pharma Inc. by XenoTherapeutics, Inc.
Firm News July 8, 2025
Gibson Dunn Represented Constellation Wealth Capital in Minority Investment in Merit Financial Advisors
Gibson Dunn advised Constellation Wealth Capital, an alternative asset management platform focused on supporting the long-term growth of independent wealth management firms, on its strategic minority investment in Merit Financial Advisors
Firm News May 8, 2025
Gibson Dunn Advises HighPost Capital in the Sale of a Controlling Interest to Azimut Group
Gibson Dunn is advising HighPost Capital, LLC in connection with the sale of a controlling interest to Azimut Group, via its U.S. subsidiary Azimut Alternative Capital Partners LLC.